TEVA

Business Context and Reporting Period

Company: Teva Pharmaceutical Industries Limited
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Strategy: Execution of "Pivot to Growth" strategy, focusing on innovative medicines, biosimilars, and cost optimization. Anda (distribution business) was reclassified from the U.S. segment to "Other Activities" effective January 1, 2026.

Key Financial Metrics

Note: Debt and Cash figures represent balances as of June 30, 2026. Q2 2025 debt balance was $16,807 million.

Material Changes vs. Prior Period

• Revenue: Q2 2026 revenue decreased 1% ($4,142M vs $4,176M) due to lower generic product sales (specifically lenalidomide/Revlimid generic), partially offset by growth in innovative products (AUSTEDO, AJOVY). Six-month revenue increased 1%.
• Profitability: Q2 2026 swung from an operating income of $455M to a loss of $231M. The primary driver was a 298% increase in R&D expenses to $970M, largely due to the acquisition of Emalex Biosciences.
• R&D Expenses: Q2 2026 R&D expenses were $970M compared to $244M in Q2 2025. This includes a $724M charge for acquired in-process R&D (IPR&D) related to Emalex's ecopipam (EBS-101).
• Legal Settlements: Expenses increased to $230M in Q2 2026 from $166M in Q2 2025, driven by provisions for antitrust litigation and updates to opioid settlement provisions.
• Segment Performance:
  • U.S. Segment: Revenue down 5%; Segment profit turned to a loss of $76M (vs $699M profit in Q2 2025) due to high R&D spend.
  • Europe Segment: Revenue down 3%; Segment profit increased 1% to $367M.
  • International Markets: Revenue up 11%; Segment profit increased 34% to $99M.

Guidance, Outlook, Risks, and Unusual Items

• Acquisition: Completed acquisition of Emalex Biosciences for ~$700M cash in June 2026. NDA submitted for ecopipam (Tourette syndrome) in June 2026. Future milestone payments up to $325M are possible.
• Legal Contingencies:
  • Opioids: Nationwide settlement agreement requires payments up to $4.25B over 13 years (including $1.2B in Narcan product). Estimated cash payments for 2026 are $379M.
  • Antitrust: Ongoing litigation regarding generic drug pricing and specific products (e.g., COPAXONE, Effexor XR, Lamictal). A provision of $117M was recorded in Q2 2026 for one ongoing antitrust matter.
  • European Commission: Fine of €462.6M regarding COPAXONE practices; appeal pending.
• Geopolitical Risks: Ongoing conflicts in the Middle East (Iran, Israel) and Russia/Ukraine create supply chain and operational uncertainty, though impact was deemed immaterial as of June 30, 2026.
• ADS Program Termination: Teva plans to terminate its American Depositary Share (ADS) program and list ordinary shares directly on the NYSE, expected to occur September 14, 2026.
• Divestiture: API business classified as "held for sale" with no assurance of timing or completion.

Investor Verification Checklist

• Emalex Integration: Verify the commercialization timeline and regulatory approval status for ecopipam (EBS-101) following the June 2026 NDA submission.
• Opioid Settlement Cash Flow: Confirm the schedule and funding sources for the $379M in estimated opioid settlement payments due in 2026.
• Antitrust Exposure: Monitor the status of the generic drug antitrust litigation (Pennsylvania MDL) and the specific provision recorded for the ongoing antitrust matter ($117M).
• ADS Transition: Verify the successful execution of the ADS-to-Ordinary Share exchange and direct NYSE listing scheduled for September 2026.
• API Divestiture: Track progress on the sales process for the API business classified as held for sale.
• Generic Competition: Assess the impact of increased competition on key generic products, particularly lenalidomide, on future U.S. segment margins.